Completed Access to Information Requests

Follow:

  • RSS
  • Cite

    Cite

    APA

    Open Government - Government of Canada. (2017, December 10). Completed Access to Information Requests. Retrieved from http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&amp%3Bamp%3Bf%5B1%5D=ss_ati_organization_en%3AAgriculture%20and%20Agri-Food%20Canada&amp%3Bamp%3Bf%5B2%5D=ss_ati_organization_en%3ASocial%20Sciences%20and%20Humanities%20Research%20Council%20of%20Canada&amp%3Bamp%3Bati%5B0%5D=ss_ati_organization_en%3AAtlantic%20Canada%20Opportunities%20Agency&amp%3Bamp%3Bati%5B1%5D=ss_ati_organization_en%3AWestern%20Economic%20Diversification%20Canada&amp%3Bati%5B0%5D=ss_ati_organization_en%3ACrown-Indigenous%20Relations%20and%20Northern%20Affairs%20Canada&ati%5B0%5D=%3ACivilian%20Review%20and%20Complaints%20Commission%20for%20the%20RCMP&ati%5B1%5D=%3AMarch&ati%5B2%5D=%3AMarine%20Atlantic%20Inc.&ati%5B3%5D=%3AMilitary%20Grievances%20External%20Review%20Committee&ati%5B4%5D=%3APublic%20Health%20Agency%20of%20Canada&ati%5B5%5D=ati_month_en%3AJuly&ati%5B6%5D=ati_organization_en%3ACanada%20Hibernia%20Holding%20Corporation&ati%5B7%5D=ati_organization_en%3AHealth%20Canada&ati%5B8%5D=ati_organization_en%3AToronto%20Port%20Authority&search_api_fulltext=&sort_by=year&sort_order=DESC&f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&page=3
    MLA

    “Completed Access to Information Requests.” Open Government - Government of Canada, 10 December 2017, http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&amp%3Bamp%3Bf%5B1%5D=ss_ati_organization_en%3AAgriculture%20and%20Agri-Food%20Canada&amp%3Bamp%3Bf%5B2%5D=ss_ati_organization_en%3ASocial%20Sciences%20and%20Humanities%20Research%20Council%20of%20Canada&amp%3Bamp%3Bati%5B0%5D=ss_ati_organization_en%3AAtlantic%20Canada%20Opportunities%20Agency&amp%3Bamp%3Bati%5B1%5D=ss_ati_organization_en%3AWestern%20Economic%20Diversification%20Canada&amp%3Bati%5B0%5D=ss_ati_organization_en%3ACrown-Indigenous%20Relations%20and%20Northern%20Affairs%20Canada&ati%5B0%5D=%3ACivilian%20Review%20and%20Complaints%20Commission%20for%20the%20RCMP&ati%5B1%5D=%3AMarch&ati%5B2%5D=%3AMarine%20Atlantic%20Inc.&ati%5B3%5D=%3AMilitary%20Grievances%20External%20Review%20Committee&ati%5B4%5D=%3APublic%20Health%20Agency%20of%20Canada&ati%5B5%5D=ati_month_en%3AJuly&ati%5B6%5D=ati_organization_en%3ACanada%20Hibernia%20Holding%20Corporation&ati%5B7%5D=ati_organization_en%3AHealth%20Canada&ati%5B8%5D=ati_organization_en%3AToronto%20Port%20Authority&search_api_fulltext=&sort_by=year&sort_order=DESC&f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&page=3
    (Report an issue with citation)
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 440 record(s)

Req # A-2022-001651

Health Canada is currently reviewing an Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate which was accepted into review on or after December 1, 2022. Identify the Canadian Reference Product, as described in section C.08.002.1 of the Food and Drug Regulations, to which the new drug in this desmopressin ANDS is compared.

Organization: Health Canada

3 page(s)
July 2023

Req # A-2022-001654

Health Canada is currently reviewing an Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate which was accepted into review on or after December 1, 2022. Please provide the name of the company (sponsor) who submitted this ANDS.

Organization: Health Canada

1 page(s)
July 2023

Req # A-2022-001655

Health Canada is currently reviewing an Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate which was accepted into review on or after December 1, 2022. Provide: the month and year that this desmopressin ANDS was accepted into review; and the status of this desmopressin ANDS’ review.

Organization: Health Canada

1 page(s)
July 2023

Req # A-2023-000011

The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Nitrofurantoin. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Nitrofurantoin which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24. 3. The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Nitrofurantoin.

Organization: Health Canada

4 page(s)
July 2023

Req # A-2023-000014

The initial cover letter and any other document indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Levetiracetam. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Levetiracetam. The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions for the medicinal ingredient Levetiracetam.

Organization: Health Canada

127 page(s)
July 2023

Req # A-2023-000037

The information the Medical Devices Directorate has on file for the Convivo System (Medical Device License No. 106067), Manufacturer CARL ZEISS MEDITEC AG as follows: Licensed indications for use of the Convivo System (Class II MDL 106067) and Copy of the Instructions For Use (IFU)/User‘s Manual/Operator‘s Manual licensed with this device.

Organization: Health Canada

181 page(s)
July 2023

Req # A-2023-000038

All information included in the submission and review of Natural Product Number (NPN) 80111110 BacoMind Children. Licence holder: Natural Remedies Private Limited, Date of Licensing: 06/30/21.

Organization: Health Canada

71 page(s)
July 2023

Req # A-2023-000054

On the 12 July 2022 under “illegal marketing of drugs and devices” a compliance letter had been sent to Boston C Canada Inc. A copy of this letter and any related material such as a follow up letter of actions.

Organization: Health Canada

34 page(s)
July 2023

Req # A-2023-000194

All current Health Canada approved labelling and currently approved intended use for: Licence No.: 98062 BTL-6000 SUPER INDUCTIVE SYSTEM ELITE.

Organization: Health Canada

37 page(s)
July 2023

Req # A-2023-000312

The National Microbiology Laboratory‘s report on BTNX‘s 200 samples.

Organization: Health Canada

8 page(s)
July 2023
Date modified: